Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles)
Data indicates INO-3107 was well tolerated and has the potential to provide